Suspendido

Inflammatory Responses in Normal Volunteers and Patients With Abnormal Immune Responses

0 criterios cumplidosConsulta de un vistazo cómo tu perfil cumple con cada criterio de elegibilidad.
Qué se está recopilando

Recolección de datos

Quiénes están siendo reclutados

Healthy Volunteers

+ Abnormal Phagocyte Function
De 6 a 65 años
Cómo está diseñado el estudio

Cohorte

Seguimiento de la incidencia de una enfermedad para identificar factores de riesgo y comprender su progresión a lo largo del tiempo.
Observacional
Inicio del estudio: abril de 1990

Resumen

Patrocinador PrincipalNational Institute of Allergy and Infectious Diseases (NIAID)
Última actualización: 6 de agosto de 2019
Extraido de una base de datos validada por el gobierno.Reclamar como socio
Fecha de inicio: 24 de abril de 1990Fecha en la que se inscribió al primer participante.

This study will investigate the inflammatory response. People with abnormal regulation of inflammation and immune defects often have an exaggerated or depressed inflammatory response that results in poor healing of recurrent infections. This study will measure and compare amounts of inflammatory mediators (chemicals involved in the inflammatory response) in healthy normal volunteers and in patients with abnormal immune responses. Healthy normal volunteers and patients with host defense defects or excessive inflammation, as in vasculitis syndromes, may be eligible for this study. Patients must be between 6 and 65 years of age. Participants will have eight small blisters raised on the forearm using a gentle suction device. The top of the blisters will be removed with scissors and a plastic template will be placed over the blisters. The wells of the template will be filled with a salt solution or a mixture of the subject s serum (fluid part of the blood without cells) and a salt solution. Some blisters may be covered with coverslips a small round piece of very thin sterilized glass before adding the fluid. Blister fluid will be removed from the wells at 3, 5, 8, and 24 hours with a syringe and analyzed for inflammatory mediators. A scab will form over the blisters and fall off in about 2 weeks. Participants will have about 4 tablespoons of blood drawn in order to compare the inflammatory mediators in the blood with those in the blister fluid. Patients with abnormal regulation of inflammation and with host defense defects often have an exaggerated or depressed inflammatory response with resultant difficulty in healing of recurrent infections. Delayed healing can be manifested by either a delay in wound healing, granuloma formation along the incision line, or dehiscence of a partially healed wound without evidence of infection. We are interested in studying the dynamics of host immune defenses during an experimentally induced inflammatory response using a well-studied suction blister device. This protocol is designed to study mediators of inflammation in patients with host defense defects as well as patients with excessive inflammation as in the vasculitis syndromes. We will measure mediators of inflammation (e.g., C5a, leukotriene B4, interleukins, chemokines, tumor necrosis factor, interferon-gamma) by ELISA, radioimmunoassay, High Performance Liquid Chromatography, multiplex cytokine assays, and/or bioactivity assays. Furthermore, molecular characterization and host defense functions (e.g., respiratory burst, chemotaxis, phagocytosis, microbicidal activity) of cells recruited to the blisters will also be examined. In addition to the analysis of cell function, RNA will be prepared and subject to DNA microarray or quantitative RT-PCR studies to measure expression and dynamics of key inflammatory mediators. Many of these factors contribute to the inflammatory process and several are thought to be important in granuloma formation. If patients are found to have abnormal amounts of these mediators when compared to healthy volunteers or patients with other abnormalities it will help us understand the basis for their disease and new therapeutic strategies. For example, this blister study allowed us to identify a patient subsequently shown to have IRAK4 deficiency.

Título OficialComparison of Inflammatory Responses in Normal Volunteers and Patients With Abnormal Phagocyte Function Using the Suction Blister Technique 
Patrocinador PrincipalNational Institute of Allergy and Infectious Diseases (NIAID)
Última actualización: 6 de agosto de 2019
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Protocolo

Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.
Detalles del Diseño
Se reclutarán 169 pacientesNúmero total de participantes que el ensayo clínico espera reclutar.
Cohorte
Estos estudios siguen a un grupo de personas con características comunes (como una condición o año de nacimiento) durante un periodo específico para analizar resultados de salud o exposiciones.

Cómo se recopila la información
Algunos estudios utilizan enfoques alternativos o combinados que no encajan estrictamente en los modelos prospectivos, retrospectivos o transversales. Estos pueden incluir cronogramas híbridos, simulaciones o métodos observacionales adaptativos.Otras formas de recopilar datos
Prospectivo
: Estos estudios recopilan nuevos datos a lo largo del tiempo del presente en adelante.

Retrospectivo
: Estos estudios utilizan historiales médicos u otros datos pasados.

Transversal
: Estos estudios recopilan datos en un momento específico.

Elegibilidad

Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.
Condiciones
Criterios
Cualquier sexoSexo biológico de los participantes elegibles para inscribirse.
De 6 a 65 añosRango de edades de los participantes que pueden unirse al estudio.
Voluntarios sanos permitidosIndica si personas sanas, sin la condición que se estudia, pueden participar.
Condiciones
Patología
Healthy Volunteers
Abnormal Phagocyte Function
Criterios

* INCLUSION CRITERIA - PATIENTS: Patients having or thought to have an immune defect between the ages of 6 and 65 years (inclusive) are eligible to participate. INCLUSION CRITERIA - NORMAL VOLUNTEERS: Be a healthy adult of either sex and between the ages of 18 and 65 years old. Weight greater than 110 pounds. Not have any heart, lung, or kidney disease, or bleeding disorders. Not have a history of viral hepatitis (B or C) since age 11. Not have a history of intravenous injection drug use. Not have a history of engaging in high-risk activities for exposure to the AIDS virus. Not be pregnant. EXCLUSION CRITERIA - PATIENTS: Patients less than 6 or greater than 65 years of age. EXCLUSION CRITERIA - NORMAL VOLUNTEER: Less than 18 years old or older than 65 years. Have viral hepatitis (B or C). HIV positive. Receiving chemotherapeutic agent(s), or have underlying malignancy. Pregnant. Have history of heart, lung, kidney disease, or bleeding disorders.


Plan de Estudio

Conoce todos los tratamientos administrados en este estudio, su descripción detallada y en qué consisten.
Objetivos del Estudio
Objetivos del Estudio
Objetivos Primarios


Centros del Estudio

Estos son los hospitales, clínicas o centros de investigación donde se lleva a cabo el estudio. Puedes encontrar la ubicación más cercana a ti y su estado de reclutamiento.
Este estudio tiene una ubicación
Suspendido
National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, United StatesVer ubicación

Suspendido1 Centros de Estudio